The human phospholamban Arg14-deletion mutant localizes to plasma membrane and interacts with the Na/K-ATPase

Journal of Molecular and Cellular Cardiology

Volumn 52, Issue 3, 2012, Pages 773-782

  Haghighi, Kobra ^a   Pritchard, Tracy ^a   Bossuyt, Julie ^b   Waggoner, Jason R ^a   Yuan, Qunying ^a   Fan, Guo Chang ^a   Osinska, Hanna ^a   Anjak, Ahmad ^a   Rubinstein, Jack ^a   Robbins, Jeffrey ^a   Bers, Donald M ^b   Kranias, Evangelia G ^a,c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Calcium cycling; Heart failure; Mutation; Phospholamban; SERCA

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) ALPHA1; ARGININE; CALCIUM; CYAN FLUORESCENT PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; NUCLEIC ACID; OXALIC ACID; PHOSPHOLAMBAN; PROTEIN KINASE B; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; UNCLASSIFIED DRUG; YELLOW FLUORESCENT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM SIGNALING; CALCIUM TRANSPORT; CARDIOVASCULAR PARAMETERS; CELL MEMBRANE; CELL STIMULATION; CONGESTIVE CARDIOMYOPATHY; CONSENSUS SEQUENCE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEART CONTRACTION; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBER MEMBRANE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SARCOPLASMIC RETICULUM; WILD TYPE;

ANIMALS; CALCIUM; CALCIUM-BINDING PROTEINS; CARDIOMEGALY; CELL MEMBRANE; ENZYME ACTIVATION; HUMANS; MALE; MICE; MICE, TRANSGENIC; MUTANT PROTEINS; MYOCYTES, CARDIAC; PROTEIN BINDING; PROTEIN TRANSPORT; SARCOPLASMIC RETICULUM; SEQUENCE DELETION; SIGNAL TRANSDUCTION; SODIUM-POTASSIUM-EXCHANGING ATPASE; VENTRICULAR REMODELING;

EID: 84857637211     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.11.012     Document Type: Article

References (46)

1. American Heart Association. http://www.americanheart.org.
2. Cohn J.N. Current concepts in the treatment of congestive heart failure. Cardiology 1997, 88:2-6.
3. Gianni D., Chan J., Gwathmey J.K., Del Monte F., Hajjar R.J. SERCA2a in heart failure: role and therapeutic prospects. J Bioenerg Biomembr 2005, 37:375-380.
4. Brini M., Carafoli E. Calcium pumps in health and disease. Physiol Rev 2009, 89:1341-1378.
5. Bers D.M. Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol 2008, 70:23-49.
6. MacLennan D.H., Kranias E.G. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 2003, 4:566-577.
7. Brittsan A.G., Kranias E.G. Phospholamban and cardiac contractile function. J Mol Cell Cardiol 2000, 32:2131-2139.
8. Ke Y., Lei M., Solaro R.J. Regulation of cardiac excitation and contraction by p21 activated kinase-1. Prog Biophys Mol Biol 2008, 98:238-250.
9. Koss K.L., Kranias E.G. Phospholamban: a prominent regulator of myocardial contractility. Circ Res 1996, 79:1059-1063.
10. Simmerman H.K., Jones L.R. Phospholamban: protein structure, mechanism of action, and role in cardiac function. Physiol Rev 1998, 78:921-947.
11. 2+ transport. Circ Res 2003, 92:769-776.
12. Tada M., Inui M., Yamada M., Kadoma M., Kuzuya T., Abe H., et al. Effects of phospholamban phosphorylation catalyzed by adenosine 3':5'-monophosphate and calmodulin-dependent protein kinases on calcium transport ATPase of cardiac sarcoplasmic reticulum. J Mol Cell Cardiol 1983, 15:335-346.
13. 2+ transport by cyclic 3',5'-AMP-dependent and calcium-calmodulin-dependent phosphorylation of cardiac sarcoplasmic reticulum. Biochim Biophys Acta 1985, 844:193-199.
14. Luo W., Wolska B.M., Grupp I.L., Harrer J.M., Haghighi K., Ferguson D.G., et al. Phospholamban gene dosage effects in the mammalian heart. Circ Res 1996, 78:839-847.
15. Kadambi V.J., Ponniah S., Harrer J.M., Hoit B.D., Dorn G.W., Walsh R.A., et al. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest 1996, 97:533-539.
16. Haghighi K., Kolokathis F., Gramolini A.O., Waggoner J.R., Pater L., Lynch R.A., et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc Natl Acad Sci U S A 2006, 103:1388-1393.
17. Posch M.G., Perrot A., Geier C., Boldt L., Schmidt G., Lehmkuhl H.B., et al. Genetic deletion of arginine 14 in phospholamban causes dilated cardiomyopathy with attenuated electrocardiographic R amplitudes. Heart Rhythm 2009, 6:480-486.
18. Chu G., Lester J.W., Young K.B., Luo W., Zhai J., Kranias E.G. A single site (Ser16) phosphorylation in phospholamban is sufficient in mediating its maximal cardiac responses to beta-agonists. J Biol Chem 2000, 275(49):38938-38943.
19. 2+ affinity by phospholamban in transgenic hearts overexpressing a non-phosphorylatable form of phospholamban. J Biol Chem 2000, 275:12129-12135.
20. Luo W., Grupp I.L., Harrer J., Ponniah S., Grupp G., Duffy J.J., et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 1994, 75:401-409.
21. 2+-ATPase superinhibition and cardiac remodeling. Circulation 2006, 113:995-1004.
22. Krenz M., Sadayappan S., Osinska H.E., Henry J.A., Beck S., Warshaw D.M., et al. Distribution and structure-function relationship of myosin heavy chain isoforms in the adult mouse heart. J Biol Chem 2007, 282:24057-24064.
23. +-ATPase in smooth muscle decreases blood pressure. Am J Physiol Heart Circ Physiol 2007, 293:H1172-H1182.
24. Bossuyt J., Despa S., Han F., Hou Z., Robia S.L., Lingrel J.B., et al. Isoform specificity of the Na/K-ATPase association and regulation by phospholemman. J Biol Chem 2009, 284:26749-26757.
25. Robia S.L., Campbell K.S., Kelly E.M., Hou Z., Winters D.L., Thomas D.D. Förster transfer recovery reveals that phospholamban exchanges slowly from pentamers but rapidly from the SERCA regulatory complex. Circ Res 2007, 101:1123-1129.
26. Despa S., Bossuyt J., Han F., Ginsburg K.S., Jia L., Kutchai H., et al. Phospholemman-phosphorylation mediates the ß-adrenergic effects on Na/K pump function in cardiac myocytes. Circ Res 2005, 97:252-259.
27. Rubinstein J., Pelosi A., Vedre A., Kotaru P., Abela G.S. Hypercholesterolemia and myocardial function evaluated via tissue Doppler imaging. Cardiovasc Ultrasound 2009, 7:56.
28. Chu G., Ferguson D.G., Edes I., Kiss E., Sato Y., Kranias E.G. Phospholamban ablation and compensatory responses in the mammalian heart. Ann N Y Acad Sci 1998, 853:49-62.
29. Menick D.R., Renaud L., Buchholz A., Müller J.G., Zhou H., Kappler C.S., et al. Regulation of Ncx1 gene expression in the normal and hypertrophic heart. Ann N Y Acad Sci 2007, 1099:195-203.
30. 2+ exchanger expression in adult cardiomyocytes. J Mol Cell Cardiol 2005, 38:735-743.
31. Eijssen L.M.T., van den Bosch B.J.C., Vignier N., Lindsey P.J., van den Burg C.M.M., Carrier L., et al. Altered myocardial gene expression reveals possible maladaptive processes in heterozygous and homozygous cardiac myosin-binding protein C knockout mice. Genomics 2008, 91:52-60.
32. Wang Y. Mitogen-activated protein kinases in heart development and diseases. Circulation 2007, 116:1413-1423.
33. Sharma P., Ignatchenko V., Grace K., Ursprung C., Kislinger T., Gramolini A.O. Endoplasmic reticulum protein targeting of phospholamban: a common role for an N-terminal di-arginine motif in ER retention. PLoS One 2010, 5:e11496.
34. Stenoien D.L., Knyushko T.V., Londono M.P., Opresko L.K., Mayer M.U., Brady S.T., et al. Cellular trafficking of phospholamban and formation of functional sarcoplasmic reticulum during myocyte differentiation. Am J Physiol Cell Physiol 2007, 292:C2084-C2094.
35. Clayton J.C., Hughes E., Middleton D.A. The cytoplasmic domains of phospholamban and phospholemman associate with phospholipid membrane surfaces. Biochemistry 2005, 44:17016-17026.
36. Shattock M.J. Phospholemman: its role in normal cardiac physiology and potential as a druggable target in disease. Curr Opin Pharmacol 2009, 9:160-166.
37. +-ATPase of the sarcoplasmic reticulum. Biochem J 2001, 356:685-704.
38. +-ATPase regulation. Fundam Clin Pharmacol 2008, 22:615-621.
39. Aperia A. New roles for an old enzyme: Na, K-ATPase emerges as an interesting drug target. J Intern Med 2007, 261:44-52.
40. Slack J.P., Grupp I.L., Dash R., Holder D., Schmidt A., Gerst M.J., et al. The enhanced contractility of the phospholamban-deficient mouse heart persists with aging. J Mol Cell Cardiol 2001, 33:1031-1040.
41. +-ATPase as a signal transducer. Eur J Biochem 2002, 269:2434-2439.
42. Gan X.T., Gong Xiang-Qun, Xue J., Haist J.V., Bai D., Karmazyn M. Sodium-hydrogen exchange inhibition attenuates glycoside-induced hypertrophy in rat ventricular myocytes. Cardiovasc Res 2010, 85:79-89.
43. Kometiani P., Tian J., Li J., Nabih Z., Gick G., Xie Z. Regulation of Na/K-ATPase b1-subunit gene expression by ouabain and other hypertrophic stimuli in neonatal rat cardiac myocytes. Mol Cell Biochem 2000, 215:65-72.
44. Dmitrieva R.I., Doris P.A. Cardiotonic steroids: potential endogenous sodium pump ligands with diverse function. Exp Biol Med 2002, 227:561-569.
45. Tian J., Xie Z. The Na-K-ATPase and calcium-signaling microdomains. Physiology 2008, 23:205-211.
46. +-ATPase signaling cascade in rat hearts. Cardiovasc Res 2007, 73:488-496.